|Other Names||Ubiquitin-conjugating enzyme E2 G1, E217K, UBC7, Ubiquitin carrier protein G1, Ubiquitin-protein ligase G1, Ubiquitin-conjugating enzyme E2 G1, N-terminally processed, UBE2G1, UBE2G|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys- 48'-, as well as 'Lys-63'-linked polyubiquitination. May be involved in degradation of muscle-specific proteins. Mediates polyubiquitination of CYP3A4.|
|Tissue Location||Widely expressed, mainly in skeletal muscle.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The modification of proteins with ubiquitin is animportant cellular mechanism for targeting abnormal or short-livedproteins for degradation. Ubiquitination involves at least threeclasses of enzymes: ubiquitin-activating enzymes, or E1s,ubiquitin-conjugating enzymes, or E2s, and ubiquitin-proteinligases, or E3s. This gene encodes a member of the E2ubiquitin-conjugating enzyme family and catalyzes the covalentattachment of ubiquitin to other proteins. The protein may beinvolved in degradation of muscle-specific proteins. [provided byRefSeq].
Hassink, G., et al. Biochem. J. 388 (PT 2), 647-655 (2005) :Kim, B.W., et al. Mol. Endocrinol. 17(12):2603-2612(2003)Gevaert, K., et al. Nat. Biotechnol. 21(5):566-569(2003)Imai, Y., et al. Cell 105(7):891-902(2001)Tiwari, S., et al. J. Biol. Chem. 276(19):16193-16200(2001)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.